Trial · NCT00922480

Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients

NCT00922480, Phase 3, Completed, Boryung Pharmaceutical Co., Ltd; results first posted 2018-02-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients. Trials, record NCT00922480. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00922480

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients
NCT number: NCT00922480
Status: Completed
Phases: Phase 3
Enrollment: 506 participants, actual
Lead sponsor: Boryung Pharmaceutical Co., Ltd
Conditions: Hypertension
Interventions: Fimasartan, Losartan (Control)
First posted: 2009-06-17
Last updated: 2018-04-10
Results first posted: 2018-02-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Diastolic Blood Pressure Change	baseline and 12 weeks	Value of DBP at 12 Weeks minus value of DBP at Baseline while in a sitting position
Secondary	Diastolic Blood Pressure Change	baseline and 4 weeks, 8 weeks	* Value of DBP at 4 Weeks minus value of DBP at Baseline while in a sitting position * Value of DBP at 8 Weeks minus value of DBP at Baseline while in a sitting position

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Diastolic Blood Pressure Change	baseline and 12 weeks	As ITT group, these are subjects who have been randomly assigned and have at least one primary end point.	mmHg	MEAN
SECONDARY	Diastolic Blood Pressure Change	baseline and 4 weeks, 8 weeks	As ITT group, these are subjects who have been randomly assigned and have at least one primary end point.	mmHg	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Diastolic Blood Pressure Change	Control: Losartan / Week 12 -ITT		-8.56	Standard Deviation 7.72	mmHg
Diastolic Blood Pressure Change	Test: Fimasartan / Week 12 -ITT		-11.26	Standard Deviation 7.53	mmHg
Diastolic Blood Pressure Change	Control: Losartan / Week 4,8 -ITT	Week 4	-5.73	Standard Deviation 6.56	mmHg
Diastolic Blood Pressure Change	Test: Fimasartan / Week 4,8 -ITT	Week 4	-8.22	Standard Deviation 7.35	mmHg
Diastolic Blood Pressure Change	Control: Losartan / Week 4,8 -ITT	Week 8	-8.01	Standard Deviation 7.16	mmHg
Diastolic Blood Pressure Change	Test: Fimasartan / Week 4,8 -ITT	Week 8	-11.01	Standard Deviation 7.63	mmHg

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Main Study	STARTED	Control: Losartan	250
Main Study	STARTED	Test: Fimasartan	255
Main Study	COMPLETED	Control: Losartan	213
Main Study	COMPLETED	Test: Fimasartan	226
Main Study	NOT COMPLETED	Control: Losartan	37
Main Study	NOT COMPLETED	Test: Fimasartan	29
Extension Study	STARTED	Control: Losartan	73
Extension Study	STARTED	Test: Fimasartan	85
Extension Study	COMPLETED	Control: Losartan	68
Extension Study	COMPLETED	Test: Fimasartan	82

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events226

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	Nervous system disorders	Control: Losartan	17	250	18
other	Headache	Nervous system disorders	Test: Fimasartan	16	255	17
other	Dizziness	Nervous system disorders	Control: Losartan	9	250	10
other	Dizziness	Nervous system disorders	Test: Fimasartan	11	255	11
other	Hypoaesthesia	Nervous system disorders	Control: Losartan	2	250	2
other	Hypoaesthesia	Nervous system disorders	Test: Fimasartan	0	255	0
other	Migraine	Nervous system disorders	Control: Losartan	0	250	0
other	Migraine	Nervous system disorders	Test: Fimasartan	2	255	2
other	Dysaesthesia	Nervous system disorders	Control: Losartan	1	250	1
other	Dysaesthesia	Nervous system disorders	Test: Fimasartan	0	255	0

1 to 10 of 226Source ClinicalTrials.gov

See all 226 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Control: Losartan
Total, all-cause mortality	Test: Fimasartan
Total, other adverse events	Control: Losartan	76	250
Total, other adverse events	Test: Fimasartan	82	255
Total, serious adverse events	Control: Losartan	5	250
Total, serious adverse events	Test: Fimasartan	3	255

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
21740078	DERIVED	PubMed
22381711	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Control: Losartan vs Test: Fimasartan: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00922480

GET https://conductscience.org/api/trials/v1/NCT00922480/events?page=2

API reference For AI assistants